Quest's $1.3 Bil. SmithKline Lab Buy Provides 10% Market Share - S&P
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics' credit rating with Standard & Poor may be downgraded over financing and integration concerns associated with the company's planned $1.3 bil. acquisition of SmithKline Beecham's Clinical Laboratories division.